Use of Genetically Informed Methods to Clarify the Nature of the Association Between Cannabis Use and Risk for Schizophrenia Nathan A. Gillespie, Kenneth S. Kendler JAMA Psychiatry, Published online November 4, 2020 Cohort studies and meta-analyses have documented a robust association between cannabis use, heavy use, and misuse with future risk of schizophrenia.1-3 Despite adjusting for covariates, including current psychotic symptoms, other psychopathology, and social integration,(1) the ability of these models to determine the degree to which cannabis causes schizophrenia is limited and dependent on their ability to capture all relevant confounders. When evaluating efforts to reduce cannabis use as a means of [...]
Lire la suiteNeurological Manifestations Associated with Synthetic Cannabinoid Use - A Case Series Marwa Elnazeir, Siddharth Narayanan, Pradeepthi Badugu, Abid Hussain, Cody B. Stephens, Riwaj Bhagat, Christopher M. Jones, Wei Liu, Alexi R. Hernandez, Kerri S. Remmel and Adriana E. Palade The Open Neurology Journal, 2020, 14, 53-58. Doi : 10.2174/1874205X02014010053 Abstract : Background : Synthetic Cannabinoid (SC) use has emerged as a growing public health threat in the United States. Several unexpected cases, presenting with a constellation of unrelated symptoms, but all having toxicity linked to SC use, have been reported in the last decade (2010-2019). Methods : We report a cluster of several independent cases where patients were [...]
Lire la suitePharmacological evaluation of new constituents of “Spice”: synthetic cannabinoids based on indole, indazole, benzimidazole and carbazole scaffolds Clara T. Schoeder, Cornelius Hess, Burkhard Madea, Jens Meiler, Christa E. Müller Forensic Toxicology, 2018, 36, 385-403. Doi : 10.1007/s11419-018-0415-z Abstract Purpose : In the present study we characterized a series of synthetic cannabinoids containing various heterocyclic scaffolds that had been identified as constituents of “Spice”, a preparation sold on the illicit drug market. All compounds were further investigated as potential ligands of the orphan receptors GPR18 and GPR55 that interact with some cannabinoids. Methods : The compounds were studied in radioligand binding assays to determine their affinity for [...]
Lire la suiteDu cannabis de synthèse dangereux sur le marché noir RESPADD, Actualité des Addictions, Savoirs , Connaissances et Pratiques, 11 octobre 2020 Il y a un an déjà, le canton de Zurich lançait l'alerte sur la présence de cannabinoïdes de synthèse dangereux sur le marché noir. Aujourd'hui, ils gagneraient la Suisse romande. Les associations de drug checking adaptent leurs offres pour intégrer les tests à ces substances. Les sites internet multiplient les alertes. Une situation qui appelle à accélérer la mise en place de dispositifs de drug checking dans toute la Suisse et d'une règlementation spécifique. Après Zurich, Bâle et Berne, du cannabis synthétique [...]
Lire la suiteTrajectories of Nicotine and Cannabis Vaping and Polyuse. From Adolescence to Young Adulthood H. Isabella Lanza, PhD; Jessica L. Barrington-Trimis, PhD; RobMcConnell, MD; Junhan Cho, PhD; Jessica L. Braymiller, PhD; Evan A. Krueger, PhD, MPH, MSW; Adam M. Leventhal, PhD JAMA Network Open, 2020, 3, (10), :e2019181. doi : 10.1001/jamanetworkopen.2020.19181 Abstract IMPORTANCE : Little is known about cannabis vaping trajectories across adolescence and young adulthood or the co-occurrence with nicotine vaping. OBJECTIVE : To evaluate nicotine vaping and cannabis vaping trajectories from late adolescence to young adulthood (18 years of age) and the extent of polysubstance vaping. DESIGN, SETTING, AND PARTICIPANTS : In this prospective cohort study, 5 surveys [...]
Lire la suiteAdolescent treatment admissions for marijuana following recreational legalization in Colorado and Washington Jeremy Mennis, Gerald J. Stahler Drug and Alcohol Dependence, 2020, 210, 107960 Doi : 10.1016/j.drugalcdep.2020.107960 A B S T R A C T Introduction : There is concern that recreational marijuana legalization (RML) may lead to increased cannabis use disorder (CUD) among youth due to increased marijuana use. This study investigates whether adolescent substance use disorder treatment admissions for marijuana use increased in Colorado and Washington following RML. Methods : Annual data on 2008–2017 treatment admissions for marijuana use from the SAMHSA TEDS-A dataset for adolescents age 12–17 were used to model state treatment [...]
Lire la suiteEmerging Evidence for Cannabis’ Role in Opioid Use Disorder Beth Wiese and Adrianne R. Wilson-Poe Cannabis and Cannabinoid Research, 2018, Volume 3.1, 179-189. Doi : 10.1089/can.2018.0022 Abstract Introduction : The opioid epidemic has become an immense problem in North America, and despite decades of research on the most effective means to treat opioid use disorder (OUD), overdose deaths are at an all-time high, and relapse remains pervasive. Discussion : Although there are a number of FDA-approved opioid replacement therapies and maintenance medications to help ease the severity of opioid withdrawal symptoms and aid in relapse prevention, these medications are not risk free nor are they successful [...]
Lire la suiteReduction of Benzodiazepine Use in Patients Prescribed Medical Cannabis Chad Purcell, Andrew Davis, Nico Moolman, and S. Mark Taylor Cannabis and Cannabinoid Research, 2019, Volume 4, Number 3, Doi : 10.1089/can.2018.0020 Abstract Background : Benzodiazepines are a class of medication with sedative properties, commonly used for anxiety and other neurological conditions. These medications are associated with several well-known adverse effects. This observational study aims to investigate the reduction of benzodiazepine use in patients using prescribed medical cannabis. Methods : A retrospective analysis was performed on a cohort of 146 medical cannabis patients (average age 47 years, 61% female, 54% reporting prior use of cannabis) who reported [...]
Lire la suiteFrequent Cannabis Use in Depression Tripled Over Past Decade Batya Swift Yasgur, MA, LSW Medscape, August 19, 2020 Not only are individuals with depression at significantly higher risk for cannabis use compared with those without depression, this trend has increased dramatically over the last decade, new research shows. Investigators analyzed data from more than 16,000 US adults between the ages of 20 and 59 years and found that those with depression had almost twice the odds of any past-month cannabis use compared with those without depression. Odds rose from 1.5 in the 2005-2006 period to 2.3 in the 2015-2016 period. Moreover, the odds ratio (OR) [...]
Lire la suiteTRIBUNE. « Après la crise du Covid-19, il faut légaliser le cannabis, vite ! » Emmenés par le député des Bouches-du-Rhône François-Michel Lambert, une soixantaine d’élus de tous bords (LREM, EELV, UDI, LFI, LR) et des médecins estiment que la légalisation du cannabis est une des solutions du monde d’après Covid-19 Par François-Michel Lambert (député et coprésident de LEF), Caroline Janvier (députée LREM), Sylvia Pinel (députée PRG) et Jean-Luc Bennahmias (membre du CESE) Publié le 18 juin 2020 à 07h00 Mis à jour le 18 juin 2020 à 19h31 https://www.nouvelobs.com/societe/20200618.OBS30192/tribune-apres-la-crise-du-covid-19-il-faut-legaliser-le-cannabis-vite.html#modal-msg Photo d’illustration. (ROBYN BECK / AFP) En juin 2019, avec une vingtaine de députés, nous déposions une proposition de [...]
Lire la suite